Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early advice: making the most of a mixed offering

This article was originally published in Scrip

Executive Summary

Early scientific advice from health technology assessment bodies is increasingly used by manufacturers to ensure their development programs and submission dossiers satisfy the requirements. Although the HTA bodies' advice is proving to be valuable to drug developers, further changes are needed to optimize the effectiveness of these new and evolving processes, as discussed at the eyeforpharma Market Access and Pricing Excellence event in Amsterdam on 3-4 June 2015.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029116

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel